Multiple Actions of the Anthracycline Daunorubicin on Cardiac Ryanodine Receptors

Amy D. Hanna, Marie Janczura, Eric Cho, Angela F. Dulhunty, and Nicole A. Beard

John Curtin School of Medical Research, Australian Capital Territory, Australia

Received May 8, 2011; accepted June 21, 2011

ABSTRACT

Our aim was to examine the molecular basis for acute effects of the anthracycline daunorubicin on cardiac ryanodine receptor (RyR2) channels and cardiac calsequestrin (CSQ2). Cardiotoxic effects of anthracyclines preclude their chemotherapeutic use in patients with pre-existing heart conditions. To address this significant problem, the mechanisms of anthracycline toxicity must be defined but at present are poorly understood. RyR2 channel activity was assessed by measuring Ca\(^{2+}\) release from cardiac sarcoplasmic reticulum vesicles and by examining single RyR2 channels inserted into artificial lipid bilayers. We show that 0.5 to 10 μM daunorubicin increases the activity of RyR2 channels after 5 to 10 min and that activity then declines to very low levels when channels are exposed to daunorubicin concentrations of ≥ 2.5 μM for a further 10 to 20 min. Extensive dissection of these effects shows for the first time that the activation results from a redox-independent binding of daunorubicin to the RyR2 complex. Novel data include the demonstration of daunorubicin binding to RyR2. We provide compelling evidence that RyR2 channel inhibition is due to the oxidation of free SH groups. The oxidation reaction is prevented by the presence of 1 mM dithiothreitol. We also present novel data showing that CSQ2 modifies the response of RyR2 to daunorubicin, but that the response of RyR2 is not dependent on daunorubicin binding to CSQ2. We suggest that binding of daunorubicin to RyR2 and CSQ2, and oxidation of RyR2, are all likely to contribute to anthracycline-induced cardiotoxicity during chemotherapy.

Introduction

Cardiac and skeletal muscle contraction is triggered by excitation-contraction coupling, the process that links depolarization of the surface membrane with Ca\(^{2+}\) release from the internal sarcoplasmic reticulum (SR) Ca\(^{2+}\) store. Ca\(^{2+}\) is released from the SR through the ryanodine receptor (RyR) Ca\(^{2+}\) channel, which forms the hub of a macromolecular complex that spans the SR membrane and includes cytoplasmic proteins and proteins in the lumen of the SR. The efficacy of Ca\(^{2+}\) release is set by the integrated effects on RyR channel activity of associated proteins/ligands, covalent modification by redox reactions and phosphorylation, and by ionic conditions. In the heart, single point mutations in the cardiac isoform of the RyR (RyR2) or the calcium binding protein calsequestrin (CSQ2, located within the lumen of the junctional SR) lead to ventricular tachycardia and sudden death (Lahat et al., 2001; Brini, 2004), whereas therapeutic drugs such as the anthracyclines can seriously disrupt RyR2 function. Anthracyclines, including daunorubicin and doxorubicin, are highly effective in the treatment of a variety of cancers. The drugs have a long half-life, accumulate in the heart at concentrations in the nanomolar and low micromolar range, and induce an ~8-fold increase in the risk of death as a result of cardiac complications (Mertens et al., 2001). The cardiac complications manifest as acute arrhythmias and hypotension and chronic conditions such as dilated cardiomyopathy and congestive heart failure (Menna et al., 2007). The cardiotoxicity is thought to result from the synergistic actions of the acute and chronic effects of the drugs on SR proteins. The acute effects are attributed to the accumulated anthracycline binding to target protein(s), whereas the chronic effects include changes in expression of Ca\(^{2+}\) handling proteins such as SERCA., but that present, are poorly understood wings, in patients with pre-existing heart conditions. To address this significant problem, the mechanisms of anthracycline toxicity must be defined but at present are poorly understood. RyR2 channel activity was assessed by measuring Ca\(^{2+}\) release from cardiac sarcoplasmic reticulum vesicles and by examining single RyR2 channels inserted into artificial lipid bilayers. We show that 0.5 to 10 μM daunorubicin increases the activity of RyR2 channels after 5 to 10 min and that activity then declines to very low levels when channels are exposed to daunorubicin concentrations of ≥ 2.5 μM for a further 10 to 20 min. Extensive dissection of these effects shows for the first time that the activation results from a redox-independent binding of daunorubicin to the RyR2 complex. Novel data include the demonstration of daunorubicin binding to RyR2. We provide compelling evidence that RyR2 channel inhibition is due to the oxidation of free SH groups. The oxidation reaction is prevented by the presence of 1 mM dithiothreitol. We also present novel data showing that CSQ2 modifies the response of RyR2 to daunorubicin, but that the response of RyR2 is not dependent on daunorubicin binding to CSQ2. We suggest that binding of daunorubicin to RyR2 and CSQ2, and oxidation of RyR2, are all likely to contribute to anthracycline-induced cardiotoxicity during chemotherapy.

Introduction

Cardiac and skeletal muscle contraction is triggered by excitation-contraction coupling, the process that links depolarization of the surface membrane with Ca\(^{2+}\) release from the internal sarcoplasmic reticulum (SR) Ca\(^{2+}\) store. Ca\(^{2+}\) is released from the SR through the ryanodine receptor (RyR) Ca\(^{2+}\) channel, which forms the hub of a macromolecular complex that spans the SR membrane and includes cytoplasmic proteins and proteins in the lumen of the SR. The efficacy of Ca\(^{2+}\) release is set by the integrated effects on RyR channel activity of associated proteins/ligands, covalent modification by redox reactions and phosphorylation, and by ionic conditions. In the heart, single point mutations in the cardiac isoform of the RyR (RyR2) or the calcium binding protein calsequestrin (CSQ2, located within the lumen of the junctional SR) lead to ventricular tachycardia and sudden death (Lahat et al., 2001; Brini, 2004), whereas therapeutic drugs such as the anthracyclines can seriously disrupt RyR2 function. Anthracyclines, including daunorubicin and doxorubicin, are highly effective in the treatment of a variety of cancers. The drugs have a long half-life, accumulate in the heart at concentrations in the nanomolar and low micromolar range, and induce an ~8-fold increase in the risk of death as a result of cardiac complications (Mertens et al., 2001). The cardiac complications manifest as acute arrhythmias and hypotension and chronic conditions such as dilated cardiomyopathy and congestive heart failure (Menna et al., 2007). The cardiotoxicity is thought to result from the synergistic actions of the acute and chronic effects of the drugs on SR proteins. The acute effects are attributed to the accumulated anthracycline binding to target protein(s), whereas the chronic effects include changes in expression of Ca\(^{2+}\) handling proteins such as SERCA.
as RyR2, CSQ2 and SERCA (the sarcoplastic endoplasmic reticulum Ca\(^{2+}\) ATPase) (Arai et al., 1998; Gambriel et al., 2002).

Anthracycline binding to SR proteins results in reduced SR Ca\(^{2+}\) storage capacity and modified Ca\(^{2+}\) release. The anthracyclines cross the surface and SR membranes, bind to CSQ2 (Charlier et al., 2005; Park et al., 2005; Kim et al., 2007), and alter RyR1 and RyR2 activity (Abramson et al., 1988; Ondrias et al., 1990; Pessah et al., 1990; Feng et al., 1999). Daunorubicin at 2.5 and 10 \(\mu M\) initially activates native RyR2 and then irreversibly inhibits the channels (Ondrias et al., 1990). Ca\(^{2+}\) release from SR vesicles is inhibited by 1 and 30 \(\mu M\) daunorubicin (Olson et al., 2000).

The mechanism of daunorubicin actions on RyR2 are not well understood and are likely to include redox modification of the protein. Daunorubicin contains a quinone moiety that undergoes redox cycling and induces oxidative tissue damage (Menna et al., 2007). This could alter RyR2 activity by decreasing the number of reactive thiol groups, either by oxidizing free -SH groups to disulfides (Abramson et al., 1988) or by transiently withdrawing electrons and shifting the redox potential of reactive thiols to more negative values (Pessah et al., 2002; Marinov et al., 2007). The RyR2 monomer contains 89 cysteine residues, 21 of which are available for oxidation with functional consequences. Doxorubicin reduces the number of free thiols on RyR1 (Feng et al., 1999). The contribution of redox modifications to anthracycline action on RyR2 remains controversial. The thiol-reducing agent dithiotreitol (DTT) prevents doxorubicin-induced inhibition of RyR2 channels (Ondrias et al., 1990) but not inhibition of Ca\(^{2+}\) release from the SR (Olson et al., 2000). The ability of daunorubicin to bind to RyR2 and directly modify channel gating has not previously been reported and is examined here.

CSQ2 is a second SR anthracycline target. Anthracyclines bind to CSQ2 with micromolar affinity (Kim et al., 2005), altering its Ca\(^{2+}\) binding capacity. Given that CSQ2 is a regulator of RyR2 (Wei et al., 2009), anthracyclines might affect SR Ca\(^{2+}\) homeostasis through modifying CSQ2 and its interaction with RyR2. There have been few studies of the effects of anthracyclines on single RyR2 channel activity. Most studies have used cardiac SR Ca\(^{2+}\) release or \(^{[3]H}\)ryanodine binding as an index of RyR2 channel function, but not the molecular mechanism of drug action on RyR2 channel activity. The possibility that CSQ2 may influence the action of anthracyclines on RyR2 channel function has not previously been investigated.

In this study, we examined the actions of daunorubicin on Ca\(^{2+}\) release from cardiac SR vesicles and on the activity of single RyR2 channels in lipid bilayers. We explored the possibility that the action of the drug is due to redox modification of reactive thiols on the RyR2 complex or to redox-independent ligand binding. We examined the effect of daunorubicin on the Ca\(^{2+}\) binding capacity of CSQ2 and whether this contributes to the anthracycline effects on RyR2 channel activity.

**Materials and Methods**

**Materials.** The monoclonal anti-RyR antibody was obtained from Abcam (Cambridge, United Kingdom). Phospholipids were obtained from Avanti Polar Lipids (Alabaster, AL). All other chemicals were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia).

**SR Vesicle Isolation, RyR2 and CSQ2 Purification.** Cardiac SR vesicles were prepared from sheep heart (Laver et al., 1995). RyRs were solubilized and purified from SR as described by Dulhunty et al. (2005). CSQ2 isolated from cardiac SR was purified by gel elution (Beard et al., 2008). CSQ2 was eluted from large vertical slab SDS polyacrylamide gels in a denaturing buffer using an 8.5% resolving gel (containing 8.5% acrylamide/bis (29:1), 0.375 M Tris-HCl, pH 8.8, 0.1% SDS, 0.05% ammonium peroxodisulfate solution, and 0.1% TEMED), and a 4% stacking gel consisting of 4% acrylamide/bis (29:1), 0.125 M Tris-HCl, pH 6.8, 0.1% SDS 0.05% ammonium peroxodisulfate solution. SDS-PAGE and Western blot are described in Beard et al. (2002). The Ca\(^{2+}\)-binding capacity of CSQ2 was determined using a 4\(^{5}\)Ca\(^{2+}\) spin dialisation binding assay (Murayama et al., 1984).

**Single Channel Recording and Analysis.** Planar bilayers separating two baths (cis and trans) were formed as described previously (Beard et al., 2002, 2005). SR vesicles (50 \(\mu g\)) were added to the cis solution so that the cytoplasmic surface of the SR and RyRs faced the cis solution after incorporation into the lipid bilayer. For vesicle incorporation, the solution compositions were: cis, 230 mM CsMS, 20 mM CsCl, 1 mM CaCl\(_2\), and 10 mM TES, pH 7.4; and trans, 30 mM CsMS, 20 mM CsCl, 1 mM CaCl\(_2\), and 10 mM TES, pH 7.4. After incorporation of a channel, trans \([Ca^{2+}]\) was raised to 250 mM with addition of 200 mM CsMS, and the cis solution was altered by the addition 1.32 mM BAPTA (free \([Ca^{2+}]\) = 1 \(\mu M\)). In some experiments, endogenous CSQ2 was dissociated from the RyR/triadin/junctin complex by exposure to a high ionic strength solution (Beard et al., 2002). Triadin and junctin are transmembrane proteins that bind to the luminal domain of RyR2. CSQ2 associates with the RyR2/triadin/junctin complex by binding to junctin and triadin (Gyorke and Terentyev, 2008; Wei et al., 2009). Electrical potentials are expressed here as cytoplasmic relative to luminal. The luminal solution was maintained at virtual ground. Single channel currents were recorded at +40 mV and −40 mV. The data were filtered at 1 kHz and sampled at 5 kHz. The mean open times of channels varies from 1 to 10 ms, and the measured dead time for the filter(s) (using a 20% discriminator) was <200 \(\mu s\) and the dead time calculated for an ideal fourth-order low-pass Bessel filter (as in the Axopatch 200A; Molecular Devices, Sunnyvale, CA) is no more than 200 \(\mu s\).

**Calcium Release Assay.** A Cary 3 spectrophotometer was used to monitor extravesicular Ca\(^{2+}\) at 710 nm, using the Ca\(^{2+}\) indicator antipyrylazo III (Dulhunty et al., 1999; Jayhillian et al., 2008). Cardiac SR vesicles (200 \(\mu g/ml\)) were added to a solution containing 100 mM KH\(_2\)PO\(_4\), 0.4 mM antipyrylazo III, 1 mM Na\(_2\)ATP, and 4 mM MgCl\(_2\) with temperature controlled at 25°C. The cuvette solution was magnetically stirred throughout the experiment. Cardiac SR vesicles were added to the cuvette, and the Ca\(^{2+}\) ATPase was activated by MgATP in the solution. The SR was loaded with four additions of 7.5 \(\mu M\) Ca\(^{2+}\). Thapsigargin (300 \(nM\)) was added to block the Ca\(^{2+}\)-ATPase (Sagara and Inesi, 1991), so that Ca\(^{2+}\) release could be specifically measured. Ruthenium red was then added to confirm that Ca\(^{2+}\) release was through the RyR and finally Ca\(^{2+}\) ionophore (A23187) was added to release Ca\(^{2+}\) remaining in the SR. In one series of experiments, daunorubicin was added 30 s after thapsigargin (Fig. 1A), to examine the ability of high concentrations of the drug to immediately stimulate Ca\(^{2+}\) release. In a second series, SR vesicles were incubated for 20 min with daunorubicin (or with vehi-
pressed as the difference between the logarithm of the ratio of the total amount accumulated by the SR. The total release is also indicative of the total amount accumulated by the SR. A, the immediate effect of daunorubicin on Ca²⁺ release upon activation of SERCA. The SR was then loaded with four additions of 7.5 μM daunorubicin. Cardiac SR vesicles were first added to the cuvette. [Ca²⁺] increased with vesicle addition and then fell as Ca²⁺ release was measured. The total amount of Ca²⁺ taken up into the SR was not altered by incubation of SR vesicles with daunorubicin.

**Statistics.** Average data are given as mean ± S.E.M. Statistical significance was evaluated using paired or unpaired Student’s t test as appropriate or analysis of variance. Numbers of observations (n) are given in tables and figure legends. RyR channel activity is notoriously variable, possibly because of differences between channels in the degree phosphorylation, nitrosylation, or oxidation (Copello et al., 1997; Marengo et al., 1998). To reduce effects of variability in control open probability (P_oC), and to evaluate parameters after daunorubicin addition (P_oN) or NEM addition (P_oN), data are expressed as the difference between the logₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐₐ¢buffer alone for control experiments) before they were added to the cuvette. The concentration of daunorubicin or vehicle buffer in the cuvette was adjusted to the incubation concentration, and the vesicles were loaded with Ca²⁺ in the usual way. Ca²⁺ release in this experiment was stimulated by 5 mM caffeine after addition of thapsigargin (Fig. 1B). Calibration curves of optical density changes with addition of 12.5 to 50 μM CaCl₂ to the cuvette solution showed that neither daunorubicin, caffeine, nor ruthenium red affected the calibration. The initial rate of daunorubicin or caffeine induced Ca²⁺ release was measured. The total amount of Ca²⁺ loaded into the SR was not altered by incubation of SR vesicles with daunorubicin.

**Results**

**Ca²⁺ release from cardiac SR vesicles.** The records of full experiments are shown in Fig. 1. There were no consistent differences between the amounts of Ca²⁺ taken up into the SR when daunorubicin was added after (Fig. 1A) or

![Fig. 1. Measurement of Ca²⁺ release from cardiac SR vesicles.](image-url)
before (Fig. 1B) store loading. This is indicated by the vertical arrows at the end of each record in Fig. 1. The height of the arrow indicates the total Ca$^{2+}$ released after thapsigargin addition, by daunorubicin or caffeine and then by the ionophore. The amount released is equal to the amount taken up and stored and is similar in the two types of experiment. To demonstrate that daunorubicin interacted with the Ca$^{2+}$ release mechanism in our hands, we examined the immediate effect of the drug on Ca$^{2+}$ release using concentrations $\geq 10 \mu M$ (Fig. 2A). The drug concentrations used to stimulate immediate Ca$^{2+}$ release were higher than those required to activate release after longer incubations in subsequent studies with SR vesicles and single RyR2 channels, and higher than clinical concentrations. This was expected as the activation by lower concentrations takes several minutes to develop (see Fig. 3 below). The initial rate of Ca$^{2+}$ release increased in a concentration-dependent manner to rates of $\sim 120$ nmoles/mg/min with 500 $\mu M$ daunorubicin (Fig. 2B, upper trace). The release was through RyR2 as it was blocked by ruthenium red. When the rate was measured 10 min after addition of 10 $\mu M$ daunorubicin, there was a significant increase in Ca$^{2+}$ release rate, in contrast to the initial rate (measured within 10 s of daunorubicin addition) which was not changed (insert Fig. 2B).

The effect of longer exposure to daunorubicin was examined by incubating vesicles with daunorubicin for 20 min before Ca$^{2+}$ uptake was initiated and $\sim 30$ min before Ca$^{2+}$ release was examined. Although the rate of Ca$^{2+}$ release after thapsigargin addition was low, there was a trend toward an increase in release after addition of 5, 10 nM daunorubicin and a significant decrease seen with 10 $\mu M$ daunorubicin. To more accurately measure Ca$^{2+}$ release, a stronger release was initiated with caffeine (Figs. 1B and 2, C–E). The rate of caffeine-induced Ca$^{2+}$ release, measured $\sim 30$ min after initial exposure to daunorubicin, increased significantly with only 5 nM and 10 nM the drug, then declined toward control levels as the concentration increased to 50 nM and was significantly depressed with 10 $\mu M$ (Fig. 2C-E). The drug concentrations required to alter Ca$^{2+}$ release during prolonged exposures were similar to those re-

---

**Fig. 2. Effects of daunorubicin on Ca$^{2+}$ release from cardiac SR.** A, daunorubicin added at concentrations of $\geq 50 \mu M$ (using the protocol in Fig. 1A) had an immediate action in increasing the rate of Ca$^{2+}$ release. Daunorubicin concentration is shown to the left of each trace. B, average rates of Ca$^{2+}$ release with indicated concentration of daunorubicin. Note the comments in the text regarding the interaction of high daunorubicin concentrations used to evoke an immediate effect of daunorubicin addition. The inset in B shows the average initial rates of Ca$^{2+}$ release (C) and the rate of Ca$^{2+}$ release measured 10 min (D) after addition of vehicle (0 $\mu M$ daunorubicin) or 10 $\mu M$ daunorubicin in one set of experiments in which daunorubicin-induced release was monitored for $\sim 11$ min. C and D, caffeine-induced Ca$^{2+}$ release from vesicles equilibrated for $\sim 30$ min in daunorubicin (20 min before the start of the experiment plus an additional 10 min during the Ca$^{2+}$ loading steps). Daunorubicin concentration is shown to the left of each trace. C, records showing the effect of equilibrating SR vesicles in 10 to 50 nM daunorubicin on caffeine-induced Ca$^{2+}$ release. D, records showing the effect of equilibrating SR vesicles 0.1 to 10 $\mu M$ daunorubicin on caffeine-induced Ca$^{2+}$ release. E, average relative rates of Ca$^{2+}$ release after addition of thapsigargin (gray symbols) and caffeine-induced Ca$^{2+}$ release (black symbols) after incubation with indicated concentrations of daunorubicin. The dotted lines under the records in A, C, and D indicate the slopes used in determining the rates of release shown in B and E. * significant difference from the control rates of release measured in the absence of daunorubicin ($\nu = 5$ for all concentrations), * at 5 and 10 nM refer to the increased caffeine-induced release only. ** a significant change from the previous concentration.
quired to alter channel activity during exposure lasting several minutes (following section). The Ca$^{2+}$ release experiments show that daunorubicin either stimulated or inhibited Ca$^{2+}$ release depending on the concentration and the duration of exposure to the drug.

**RyR2 channels in lipid bilayers.** Daunorubicin was added to the luminal (trans) solution bathing RyR2 channels in lipid bilayers. Daunorubicin concentrations of 500 nM and 1 µM increased RyR2 activity after several minutes (Fig. 3, A and C) and the increased activity was maintained for the duration of exposure to daunorubicin (up to 40 min). Activity increased more rapidly with higher drug concentrations (compare the rates of change in $P_o$ during exposure to 1 µM and 2.5 µM daunorubicin (Fig. 3, C and D) and average data in Table 1). With higher drug concentrations (2.5 µM and 10 µM), activity first increased and then declined (Fig. 3, B and D), to levels which were significantly less than the maximum activity and less than that before daunorubicin addition. The very low activity was maintained for the lifetime of the experiment (up to 40 min). The activity of the channel in Fig. 3C was enhanced between 7.5 and 20 min exposure to 1 µM daunorubicin and then declined after 20 min to levels that were less than the maximum, but higher than before drug addition. This fall in activity may reflect a slow onset inhibition with 1 µM daunorubicin. We apply the term “activation phase” to the period within ~3 to 8 min after daunorubicin application when $P_o$ was first enhanced compared with preceding “control” levels before drug addition and the term “inhibitory phase” as periods between ~11 and 13 min with $\leq 2.5$ µM when $P_o$ was depressed compared with initial levels.

**Fig. 3.** The activity of RyR2 is modified by daunorubicin. A and B, 3-s traces of native RyR2 channel activity at ±40 mV. Channels open upward from zero current (C, continuous line) to maximum open conductance (O, broken line). A, top panel, control recording; middle and bottom panel, after the addition of 1 µM daunorubicin to the trans chamber, maximal RyR2 activity was measured at 11 min in this channel, with no further change in activity recorded for 20 min after daunorubicin addition. B, top panel, control recording from different native RyR2 channel; middle and bottom panel, after the addition of 10 µM daunorubicin to the trans chamber, maximal RyR2 activity was measured at 11 min in this channel, with no further change in activity recorded for 20 min after daunorubicin addition. C and D, $P_o$ was measured every 10 s throughout experiments with 1 µM daunorubicin (C) or 2.5 µM daunorubicin in (D) at ±40 mV (dark gray bins) and −40 mV (light gray bins). E and F, combined data from measurements of $P_o$ at ±40 mV and −40 mV (n = 8, 12 at each concentration). Data is presented as average relative $P_o$ (log rel $P_o$, i.e., log$_10$ [F$_{act}]/$F$_{ad}$] − log$_10$ [F$_{act}$] (see Materials and Methods). Average relative $P_o$ during the activation phase is shown in E and average relative $P_o$ during the inhibitory phase shown in F. * highly significant difference from the control $P_o$ recorded before adding daunorubicin. #, significant difference between $P_o$ during the activation and inhibitory phase.
Channel open probability \( (P_o) \) with daunorubicin \( (P_{\text{ad}}) \) relative to the control \( (P_{\text{ad}}, \text{before drug addition}) \) for each channel was calculated and average relative \( P_o \) increased significantly after incubations with \( \geq 500 \text{ nM} \) daunorubicin (Fig. 3E). Concentrations \( > 1 \text{ \mu M} \) produced a significant inhibition at longer times. The relative \( P_o \) during the inhibition phase was significantly lower than the previously activated \( P_o \) and significantly lower than control activity (Fig. 3F). The channels remained inhibited for the lifetime of the bilayer (Fig. 3D).

**TABLE 1**

<table>
<thead>
<tr>
<th>Daunorubicin</th>
<th>Time to Activation Phase</th>
<th>Time to Inhibition Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control RyR2</td>
<td>10 nM</td>
<td>500 nM</td>
</tr>
<tr>
<td>CSQ(−) RyR2</td>
<td>15.0 ± 4.0</td>
<td>7.9 ± 2.5</td>
</tr>
<tr>
<td>Native RyR2</td>
<td>8.1 ± 2.0</td>
<td>3.0 ± 3.3</td>
</tr>
<tr>
<td>NativeCSQ(−)</td>
<td>11.1 ± 1.3*</td>
<td>12.6 ± 4.3</td>
</tr>
<tr>
<td>RyR2</td>
<td>10 μM</td>
<td>4.0 ± 1.1</td>
</tr>
<tr>
<td>CSQ(−) RyR2</td>
<td>11.5 ± 1.9</td>
<td>17.6 ± 0.7</td>
</tr>
</tbody>
</table>

* Significant difference between time to activation in native RyR2 (containing CSQ2) and RyR2 channels lacking CSQ2 (CSQ(−)RyR2).

**Reversibility of Daunorubicin-Induced Activation and Inhibition.** To determine whether the effects of daunorubicin on RyR2 were reversible, we examined the effect of perfusing the trans chamber with trans solution lacking daunorubicin. Disulfide formation cannot be reversed by removing the oxidizing reagent, although it can be reversed by addition of reducing reagents. Thus recovery after perfusion of the trans chamber (removal of daunorubicin) would indicate that the effect had not been due to oxidation of free -SH groups to -S-S- moieties. We found that perfusion after activation by 1 μM daunorubicin was followed (after 4.0 ± 0.8 min) by a reduction in channel activity to control levels that were maintained for the duration of the experiment (Fig. 4, A and B). This washout reversibility suggested that the increase in activity was likely to be due either to the drug binding to RyR2 or to transient redistribution of electrons in the presence of the drug without chemical modification (Marinov et al., 2007), as opposed to the oxidation of free -SH groups to form -S-S-. Many thiol reagents have a redox potential and can also alter RyR2 function by electron redistribution within free -SH groups without making or breaking disulfide bonds (Pessah et al., 2002; Marinov et al., 2007). The effects of electron redistribution are reversed by removing the agents or by adding oxidizing or reducing reagents to...
normalize the redox potential of the environment surrounding the free -SH group. The washout experiments do not distinguish between cytoplasmic, transmembrane, or luminal binding/modification sites, because daunorubicin is lipid-soluble and equilibrates across the bilayer and could therefore bind to sites located on the luminal, intramembrane, or cytoplasmic face of the RyR2 complex. Daunorubicin would re-equilibrate across the bilayer after perfusion of the trans chamber, and the concentration in the lipid and cytoplasmic compartments would be similarly reduced.

To determine whether daunorubicin increased RyR2 activity by binding to the protein or by causing a transient redistribution of electrons, we examined drug binding to RyR2. Daunorubicin was coupled to CNBr-activated Sepharose and incubated with purified RyR2. The eluate was electrophoresed, and after Western blot, the RyR2 was detected with an anti-RyR antibody. The strong immunostaining (Fig. 4E) indicated that daunorubicin bound specifically to the RyR2 protein. After preincubating RyR2 with CNBr-activated Sepharose to eliminate nonspecific binding, the RyR2 bound strongly to the daunorubicin coupled CNBr-activated Sepharose (data not shown). RyR2 did not bind to activated Sepharose in the absence of daunorubicin (Fig. 4E).

In contrast to daunorubicin-induced activation, inhibition by 2.5 μM daunorubicin was not relieved by perfusion of the trans chamber (Fig. 4, C and D). Thus daunorubicin-induced inhibition is likely to be due either to a chemical modification, such as oxidation of free -SH groups to -S-S- bonds, which cannot be reversed (reduced) simply by drug removal, or to ligand binding to a high-affinity or inaccessible site that becomes buried after binding.

**DTT Protection of Free -SH Groups and Reduction of -S-S-.** The potential role of -SH modification was examined using DTT, a strong reducing agent used to protect free thiols from oxidation to -S-S- groups and from electron withdrawal or to reduce -S-S- bonds (Cleland, 1964; Eager et al., 1997). Prevention or reversal of either activation or inhibition by DTT would indicate effects due to redox modification of free thiol groups. DTT at 1 mM prevents RyR2 oxidation (Eager et al., 1997; Eager and Dulhunty, 1999), and its addition to the cis or trans chamber can indicate the location of the reactive -SH groups, because DTT is not highly lipid soluble at pH 7.4 and does not cross the bilayer in significant amounts. Because the thiol groups of DTT have pKₐ values of 9.1 and 10.2 (Zhang et al., 1991) and the pH of the bilayer solutions was buffered to 7.4, DTT would be predominantly in its water soluble, ionized form (White, 1999) and would be unable to easily cross the lipid bilayer (White, 1999; Rang, 2007).

**DTT in the trans Solution.** DTT (1 mM) added to the trans solution before 10 μM daunorubicin (Fig. 5, A and B) did not alter RyR2 activity or prevent the usual increase and then decrease in channel activity. Likewise, 1 mM DTT added to the trans chamber after daunorubicin-induced inhibition did not reverse the inhibition (Fig. 5, C and D). Therefore, if -SH groups are modified to alter RyR2 activity, they are not located on the SR luminal side of the RyR2 complex.

**DTT in the cis Solution.** DTT in the cis solution did not alter activation by 10 μM daunorubicin but did prevent the inhibitory action of the drug (Fig. 6A). Channel activity increased and remained greater than control for up to 25 min after 10 μM daunorubicin addition (Fig. 6B). This result suggests that the inhibitory effect of daunorubicin is caused by oxidation of free thiol groups on the cytoplasmic domain of the RyR2 complex. The persistence of activation with DTT in the cis or the trans solution indicated that activation was due neither to oxidation of free -SH groups to -S-S- nor to electron withdrawal effects. Surprisingly, channel activity remained at very low values when DTT was added to the cis chamber after inhibition by 10 μM daunorubicin (Fig. 6, C and D), indicating that DTT did not reverse inhibition once it had been established. This apparent contradiction might be explained if the -S-S- were to become buried in the protein after its formation and if the -S-S- were inaccessible to DTT (see Discussion).

**N-Ethylmaleimide Probe for Modification of Free Sulfhydryl Groups.** The results thus far show two actions of daunorubicin on the RyR2 channel complex. One, activation is not dependent on redox modification and is most likely the consequence of a direct interaction between daunorubicin and the RyR2 complex. Two, the delayed inhibitory effect seems to be redox-sensitive in that it can be prevented if DTT is present in the cytoplasmic solution before daunorubicin is added. To further explore the involvement of free -SH groups, we modified (alkylated) free -SH groups on the RyR2 complex with NEM before adding daunorubicin.

NEM alone influenced RyR2 channel activity. Pₒ fell progressively for 30 min after addition of 10 mM NEM to the cis solution (Fig. 7A). NEM is highly lipid-soluble (Abbott and Schachter, 1976) and presumably equilibrated across the bilayer to alkylate -SH groups on luminal, cytoplasmic, and transmembrane parts of the RyR2 complex. When 10 μM daunorubicin was added ~9 min after NEM (Fig. 7B), the decline in activity seen with NEM alone seemed to be halted. Channel activity remained less than control but did not decline to levels seen with exposure to NEM alone (Fig. 7A). To evaluate the effect of daunorubicin in the presence of NEM, Pₒ with daunorubicin was normalized to Pₒ in NEM before daunorubicin addition (NEM control) in each channel and average data shown in Fig. 7C. This normalization procedure facilitated interpretation of the effects of daunorubicin alone on the NEM background by removing the specific effect of NEM. Relative Pₒ increased above the NEM control after 10 min and remained greater than the NEM control for the next 20 min. The increase in Pₒ was reminiscent of the activation phase seen in the absence of NEM (Figs. 3–6).

Relative Pₒ during the activation and inhibitory phases after 10 μM daunorubicin application in normal and NEM-alkylated channels are compared in Fig. 7D. There is a significant increase in relative Pₒ during the activation phase in both cases, with no significant difference between the relative increases in activity. The significant fall in Pₒ to less than control levels in the inhibition phase in normal channels is not seen in the NEM-modified channels, where relative Pₒ in the inhibitory phase was not significantly different from that in the activation phase. There was a trend toward a decline in Pₒ (Fig. 7, C and D) that may have been due to a residual inhibitory effect of daunorubicin but was more likely to be due to continued NEM action shown in Fig. 7A. It is noteworthy that relative Pₒ during the inhibitory phase in NEM-modified channels did not fall below the control level recorded before daunorubicin application. The difference between relative Pₒ in the normal and NEM-modified channels in the inhibitory phase was significant, thus the normal
daunorubicin-induced inhibition seems to have been largely prevented by NEM alkylation. This is consistent with the possibility that free -SH groups that are normally oxidized by daunorubicin and produce channel inhibition were modified by NEM and no longer available to be oxidized by daunorubicin.

Influence of CSQ2 on Daunorubicin-Induced Changes in RyR2 Activity. Because anthracyclines bind to CSQ2 (Kim et al., 2005) and CSQ2 modifies RyR2 activity (Wei et al., 2009), the effects of daunorubicin on RyR2 may have been mediated by daunorubicin binding to CSQ2, which remains associated with RyR2 channels when they are incorporated into the bilayer with SR vesicles (Beard et al., 2002; Wei et al., 2009). To determine whether CSQ2 influenced the response of RyR2 to daunorubicin, endogenous CSQ2 was selectively dissociated from the RyR/triadin/junctin complex by exposing the luminal side of native RyR2 channels to a high ionic strength solution (500 mM Cs⁺) after channel incorporation into lipid bilayers (Beard et al., 2002). A decrease in activity associated with CSQ2 dissociation from RyR2 was observed (Wei et al.,

Fig. 5. Effect of DTT in the trans solution on the action of daunorubicin. A and C, 3-s traces of native RyR2 channel activity at +40 mV. Channels open upward from zero current (C, continuous line) to maximum open conductance (O, broken line). A, first panel, control activity; second panel, addition of 1 mM DTT to the trans solution; third and fourth panels, 10 min (third panel) and 25 min (fourth panel) after the addition of 10 μM daunorubicin to the trans solution. C, first panel, control activity; second and third panel, 6 min (second panel) and 12 min (third panel) after the addition of 10 μM daunorubicin to the trans solution; fourth panel, after the addition of 1 mM DTT to the trans solution. B and D, show average combined data for Pₒ at +40 mV and −40 mV (n = 14 in B and n = 10 in D). *, significant difference from the control Pₒ recorded before adding daunorubicin. #, significant difference between Pₒ during the activation and inhibitory phase of daunorubicin action.
2009), and then the trans chamber was perfused to remove dissociated CSQ2 and return the ionic strength to the usual 250 mM. The RyR2 channels lacking CSQ2 responded to 2.5 μM daunorubicin in a similar manner to native RyR2s containing CSQ2 (Fig. 8). An initial increase in channel activity (from a $P_o$ of 0.06 ± 0.01 to 0.15 ± 0.03) was followed by a decline in $P_o$ to 0.05 ± 0.01. Relative $P_o$ in the activation phase was similar in normal channels and channels lacking CSQ2 (Fig. 8). Relative $P_o$ fell significantly in the inhibitory phase in the absence of CSQ2 but was not significantly less than control and was significantly greater than the relative $P_o$ during the inhibitory phase in normal channels. Thus, the absence of CSQ2 reduced the magnitude of daunorubicin-induced inhibition.

Although the absence of CSQ2 had no significant effect on the degree of activation induced by daunorubicin, the time taken to reach maximum activity was significantly longer than in RyR2 channels from which CSQ2 had not been dissociated (Table 1). The time to reach a minimum during the inhibitory phase of daunorubicin action also tended to be longer in the absence of CSQ2, but the change was not statistically significant. These results suggest that daunorubicin’s interactions with RyR2 are modulated by CSQ2 but do not primarily depend on daunorubicin’s association with CSQ2. Daunorubicin’s interaction with RyR2 may be modified by changes in the channel induced by CSQ2 binding to triadin and/or junctin.

Daunorubicin could influence Ca$^{2+}$ release from cardiac SR by modifying the Ca$^{2+}$ binding capacity of CSQ2 and hence the amount of Ca$^{2+}$ stored in the SR. We found that 2.5 μM daunorubicin reduced the capacity of CSQ2 for Ca$^{2+}$ binding to >70% of that in the absence of the drug at all concentrations of Ca$^{2+}$ tested (Table 2). It is not clear from the present experiments how the effects on Ca$^{2+}$ binding capacity may translate into alterations in the way CSQ2 regulates Ca$^{2+}$ release through RyRs but it is likely to reduce the amount of Ca$^{2+}$ available for release during systole.

**Discussion**

We show two separate actions of the chemotherapeutic agent daunorubicin on RyR2 channels, with novel observations on the nature, time, and concentration dependence of these effects. We show for the first time that daunorubicin-induced activation of RyR2 is not due to redox modification but probably follows daunorubicin binding to RyR2, which we also directly demonstrated for the first time. The results indicate that the slower inhibitory phase of daunorubicin’s

![Fig. 6. Effect of DTT in the cis solution on the action of daunorubicin.](image-url)
action that is mediated by -S-S- formation at a site or sites accessible from the cytoplasmic side of RyR2. Unexpectedly, CSQ2 binding to RyR2 modulates the effects of daunorubicin on the channel, but the effects are not due to daunorubicin binding to CSQ2. However daunorubicin may reduce Ca\(^{2+}\) release through RyR2 by reducing the Ca\(^{2+}\) binding capacity of CSQ2 and hence the Ca\(^{2+}\) load in the SR.

The results do not exclude the possibility that the effects of daunorubicin on RyR2 are mediated by influences of the drug on associated proteins that modulate RyR2 activity, although preliminary data indicate that purified RyR2 channels respond to daunorubicin in the same way as the native channels.

**The Activation Phase.** The daunorubicin-induced increase in activity was reversed when the drug was removed, which suggests that the increased activity was due either to drug binding or to transient electron redistribution within reactive thiol groups (Pessah et al., 2002; Marinov et al., 2007) as distinct from oxidation of thiols to disulfides (Eager and Dulhunty, 1999). The increase in \(P_o\) was observed more quickly after application at higher daunorubicin concentrations and apparently saturated with 1 \(\mu\)M daunorubicin. The saturation may have been due to the onset of inhibition, masking further increases in activity. However, activity did not increase beyond this maximum when inhibition was prevented either by DTT in the cis chamber or by NEM treatment, suggesting that the maximum response was achieved.

![Graph A](image1)

**Fig. 7.** Effect of NEM alkylation on the actions of daunorubicin. A to C, combined data from measurements of \(P_o\) at \(+40\) mV and \(-40\) mV. The effect of NEM alone is shown in A (\(n = 6\)). Data in A are presented as average relative \(P_o\) (log rel \(P_o\)) i.e., \(\log_{10}(P_o) - \log_{10}(P_o^0)\): \(P_o\) in NEM relative to \(P_o\) before adding NEM (see Methods). The effect of adding 10 \(\mu\)M daunorubicin after 9 min exposure to NEM is shown in B and C (\(n = 14\)). Data in B are presented as \(P_o\) after adding daunorubicin relative to \(P_o\) at the start of the experiment before NEM addition (log rel \(P_o\)) i.e., \(\log_{10}(P_o/P_o^0)\). Data in C are presented as \(P_o\) after adding daunorubicin relative to \(P_o\) in NEM before daunorubicin addition (log rel \(P_o\)) i.e., \(\log_{10}(P_o/P_o^0)\). Data in D are presented as relative \(P_o\) after adding daunorubicin relative to \(P_o\) in native RyR2 and CSQ2-RyR2 before adding daunorubicin (log rel \(P_o\)) i.e., \(\log_{10}(P_o/P_o^0)\). Data in D are presented as relative \(P_o\) after adding daunorubicin relative to \(P_o\) before adding daunorubicin: log rel \(P_o\) i.e., \(\log_{10}(P_o/P_o^0)\). *Significant difference from \(P_o\) before NEM addition: log rel \(P_o\) i.e., \(\log_{10}(P_o/P_o^0)\). ** significant difference between \(P_o\) and \(P_o\) before adding daunorubicin. # significant difference between \(P_o\) and \(P_o\) in the absence of daunorubicin.

![Graph B](image2)

**Fig. 8.** Daunorubicin effects on RyR2 do not depend on CSQ2. Combined data for \(P_o\) at \(-40\) mV and \(+40\) mV for native RyR2 channels (RyR2+CSQ2) (\(n = 13\)) and for RyR2 after dissociation of CSQ2 (RyR2-CSQ2) (\(n = 10\)). Data is presented as average relative \(P_o\) (log rel \(P_o\), i.e., \(\log_{10}(P_o/P_o^0)\)) *Significant difference from control activity before adding daunorubicin, # significant difference between \(P_o\) during the activation and inhibitory phases of daunorubicin action. @ significant difference between average \(P_o\) in native RyR2 and CSQ(-) RyR2 in the inhibitory phase.

**Table 2**

<table>
<thead>
<tr>
<th>Ca(^{2+}) Binding Capacity</th>
<th>No Daunorubicin</th>
<th>2.5 (\mu)M Daunorubicin</th>
</tr>
</thead>
<tbody>
<tr>
<td>nmol Ca(^{2+}) /mg purified CSQ2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1 mM</td>
<td>131 ± 15</td>
<td>97 ± 9*</td>
</tr>
<tr>
<td>1.0 mM</td>
<td>168 ± 16</td>
<td>120 ± 11*</td>
</tr>
<tr>
<td>1.5 mM</td>
<td>194 ± 19</td>
<td>134 ± 14*</td>
</tr>
</tbody>
</table>

*Significant difference between Ca\(^{2+}\) binding capacity of CSQ2 in the presence and absence of 2.5 \(\mu\)M daunorubicin (n = 8–16).
with 1 μM daunorubicin. The activation site could not be identified as being on the cytoplasmic, transmembrane, or luminal domain of the RyR2 complex because the hydrophobic drug would have equilibrated rapidly across the bilayer and could bind to a hydrophobic pocket within the RyR2 protein complex, either within membrane spanning regions, luminal residues, or microdomains in the cytoplasmic assembly.

It should be noted that oxidation of “exposed” -SH groups by low concentrations of oxidants leads to RyR2 activation. When the oxidant concentration increases, oxidation of less accessible -SH groups leads to inhibition and both activation and inhibition are prevented by DTT (Eager et al., 1997; Eager and Dulhunty, 1999). That we did not see oxidation-induced activation in the present experiments is curious. One possibility is that the anthracyclines bind to RyR2 near the "exposed" SH groups and prevent their oxidation to disulfides, perhaps by sterically hindering the required close interaction between two -SH groups.

The Inhibitory Phase. Inhibition was not reversed by drug washout, indicating that it either depended on oxidation of free -SH groups to -S-S-, that the inhibition depended on binding that was very high affinity, or that the site was inaccessible to the bulk solution. The fact that inhibition was prevented by the presence of DTT and by NEM-modification indicated that it depended on -SH oxidation. Although DTT is weakly lipid soluble at pH ~7.4 (see Results and Zhang et al., 1991; White, 1999; Rang, 2007), it does not cross the bilayer within the duration of a bilayer experiment and is thus useful for studying the sidedness of the inhibitory interaction (Eager and Dulhunty, 1999). Because DTT in the cis, but not trans, solution prevented inhibition, the -S-S- was likely formed on the cytoplasmic side of the channel complex or in a region accessible to the cytoplasmic solution. Other redox modifications, such as S-glutathionylation or S-nitrosylation (Hidalgo and Donoso, 2008), or reactions involving reactive oxygen species produced by redox cycling of the daunorubicin quinone moiety (Minotti et al., 2004; Menna et al., 2007), would not be significant in our system because the substrates and/or necessary mitochondrial enzymes are not present in the SR vesicle preparation.

Curiously, although DTT in the cis solution prevented the inhibition of RyR2 with daunorubicin, addition of DTT to the cis solution after inhibition had been established failed to restore channel activity. There are numerous examples of DTT preventing disulfide formation but not reducing the disulfide (Eager et al., 1997; Terentyev et al., 2008). The -S-S- groups becoming buried in the protein and inaccessible to the solution explain this apparent contradiction.

CSQ2 as an Anthracycline Target. The interaction between daunorubicin and RyR2 did not depend on CSQ2 because both the activation and inhibitory phases were seen either when CSQ2 was bound to RyR2 or after CSQ2 dissociation from RyR2. However, CSQ2 did modify rate of activation and the extent of inhibition. We speculate that CSQ2 binding may cause a conformational change in the RyR2, exposing the daunorubicin activation site and allowing faster activation by daunorubicin. CSQ2 binding to junctin and/or triadin, for example, may induce secondary conformational changes in RyR2 that expose the daunorubicin binding site. The lesser inhibition of RyR2 in channels lacking CSQ2 could be explained if CSQ2 removal altered RyR2 structure in a manner that reduced the impact of disulfide formation on channel gating.

Daunorubicin binding to CSQ2 reduces its Ca²⁺ binding capacity. Because CSQ2 polymers have a higher Ca²⁺ binding capacity than monomers or dimers, daunorubicin might prevent CSQ2 polymerization and thus lower its Ca²⁺ binding capacity. However, CSQ2 (in contrast to the skeletal form of CSQ) is monomeric at physiological ionic strength (~150 mM) and Ca²⁺ concentrations (~1 mM) (Park et al., 2005; Wei et al., 2009). Thus, the reduced Ca²⁺ binding capacity is unlikely to be linked to polymerization, but it could be associated with some unfolding of the monomer induced by daunorubicin binding.

Effects of Altered RyR2 Activity on SR Function and Heart Failure. Anthracyclines cause severe disruption of SR Ca²⁺ handling, depleting the SR of its Ca²⁺ load and causing cytoplasmic Ca²⁺ overload (Holmberg and Williams, 1990; Shan et al., 1996; Shadle et al., 2000). The elevated cytoplasmic Ca²⁺ triggers delayed after-depolarizations, tachycardia, and arrhythmias, which are symptomatic of acute anthracycline-induced cardiotoxicity and heart failure (Shan et al., 1996; Györke and Terentyev, 2008). Prolonged Ca²⁺ overload also leads to some of the chronic effects of anthracycline treatment and heart failure, including cardiomyocyte apoptosis and necrosis (Zucchi and Ronca-Testoni, 1997; Kumar et al., 2001; Jessup and Brozena, 2003; Minotti et al., 2004; Nakayama et al., 2007).

Our results indicate that the RyR2-dependent contribution to disruption of Ca²⁺ handling by daunorubicin would depend on the accumulated concentration of the drug in the myocytes. Increased RyR2 activity with low concentrations would contribute to delayed after-depolarizations and arrhythmia in the early acute phase of daunorubicin toxicity. The inhibitory phase would become apparent after longer exposures and with higher accumulated drug concentrations. Inhibition of RyR2 channels can also lead to ventricular fibrillation through the generation of early after-depolarizations (EADs) when the action potential is prolonged (Bers, 2002; Gomez and Richard, 2004). EADs occur when L-type Ca²⁺ channels inactivation is slowed as a result of reduced Ca²⁺ release through RyR2 and a consequently lower than normal cytoplasmic Ca²⁺ concentration (Bers, 2002). This is seen in heart failure when Ca²⁺ stores are depleted or with loss-of-function mutations in RyR2 (Gomez and Richard, 2004) and could occur during the inhibitory phase of daunorubicin action. The reduced Ca²⁺ binding capacity of CSQ2 in the presence of daunorubicin would further contribute to EADs, by reducing SR Ca²⁺ load and Ca²⁺ available for release. The extent that daunorubicin metabolites alter RyR2 function and contribute to the effects of the parent compound remains to be determined.

To conclude, we describe a biphasic modulation of single RyR2 channels by clinically relevant concentrations of daunorubicin. Channels are initially activated and then inhibited by the drug. We provide evidence that the activation is caused by a redox-independent interaction between daunorubicin and RyR2, whereas inhibition is due to the oxidation of thiol groups. Daunorubicin reduces the Ca²⁺ binding capacity of CSQ2 but this does not mediate the effects of daunorubicin on RyR2. Our study provides important new information on the functional consequences of anthracycline binding to two of its targets in the SR of cardiomyocytes,
which may help in the eventual design of anthracyclines that do not detrimentally alter Ca$^{2+}$ signaling in the heart.

Acknowledgments
We are grateful to S. Pace and J. Stivala for assistance.

Authorship Contributions
Participated in research design: Hanna, Dulhunty, and Beard.
Conducted experiments: Hanna, Janzcura, Cho, and Beard.
Performed data analysis: Hanna, Dulhunty, and Beard.
Wrote or contributed to the writing of the manuscript: Hanna, Dulhunty, and Beard.

References